BR9914251A - Formulações orais de liberação sustentada - Google Patents

Formulações orais de liberação sustentada

Info

Publication number
BR9914251A
BR9914251A BR9914251-1A BR9914251A BR9914251A BR 9914251 A BR9914251 A BR 9914251A BR 9914251 A BR9914251 A BR 9914251A BR 9914251 A BR9914251 A BR 9914251A
Authority
BR
Brazil
Prior art keywords
sustained release
release formulations
oral sustained
rivastigmine
delivering
Prior art date
Application number
BR9914251-1A
Other languages
English (en)
Inventor
Joerg Ogorka
Oskar Kalb
Rajen Shah
Satish Chandra Khanna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9914251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9914251A publication Critical patent/BR9914251A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: <B>"FORMULAçõES ORAIS DE LIBERAçãO SUSTENTADA"<D>. Composição farmacêutica capaz de liberar uma dose terapeuticamente eficaz de agente ativo, por exemplo, Rivastigmina, em um modo controlado pelo tempo.
BR9914251-1A 1998-10-01 1999-10-01 Formulações orais de liberação sustentada BR9914251A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
PCT/EP1999/007298 WO2000019985A2 (en) 1998-10-01 1999-10-01 New sustained release oral formulations

Publications (1)

Publication Number Publication Date
BR9914251A true BR9914251A (pt) 2001-06-19

Family

ID=27547321

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914251-1A BR9914251A (pt) 1998-10-01 1999-10-01 Formulações orais de liberação sustentada

Country Status (23)

Country Link
US (5) US20010033866A1 (pt)
EP (1) EP1121104B1 (pt)
JP (1) JP4012689B2 (pt)
KR (1) KR100603900B1 (pt)
CN (1) CN1406126A (pt)
AT (1) ATE286725T1 (pt)
AU (1) AU764866B2 (pt)
BR (1) BR9914251A (pt)
CA (1) CA2342340C (pt)
CZ (1) CZ302888B6 (pt)
DE (1) DE69923200T2 (pt)
ES (1) ES2237163T3 (pt)
HK (1) HK1052473A1 (pt)
HU (1) HUP0103883A3 (pt)
ID (1) ID27504A (pt)
IL (2) IL141762A0 (pt)
NO (1) NO331689B1 (pt)
NZ (1) NZ510683A (pt)
PL (1) PL196945B1 (pt)
PT (1) PT1121104E (pt)
SK (1) SK285250B6 (pt)
TR (1) TR200100931T2 (pt)
WO (1) WO2000019985A2 (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1406126A (zh) 1998-10-01 2003-03-26 诺瓦提斯公司 新型缓释口服制剂
AU1738800A (en) * 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
CA2380333A1 (en) * 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
ES2284709T3 (es) * 2000-09-29 2007-11-16 Solvay Pharmaceuticals B.V. Formulacion farmaceutica de liberacion sostenida independiente de la fuerza ionica.
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
DE60223695T2 (de) * 2001-09-14 2008-10-30 Scolr, Inc., Redmond Aminosäure-modulierte dosierform mit verlängerter freisetzung
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
US20060160079A1 (en) * 2002-08-07 2006-07-20 Lane Roger M Methods for the treatment of dementia based on apo e genotype
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) * 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
KR101087464B1 (ko) * 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
WO2006020534A2 (en) * 2004-08-09 2006-02-23 Dr. Reddy's Laboratories Ltd. Stabilized desloratadine composition
EP1909770B1 (en) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
EP1879583A2 (en) * 2005-05-03 2008-01-23 Mutual Pharmaceutical Company, Inc. Quinine formulations
EP1938842A4 (en) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION COMPRISING IMPROVED CRASHING CHARACTERISTICS
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
CN104803957A (zh) 2007-04-02 2015-07-29 泰拉科斯有限公司 苄基化糖苷衍生物及其用法
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
WO2009026537A1 (en) 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use
EP2197454A4 (en) * 2007-09-25 2012-07-04 Idexx Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
PT2324002T (pt) 2008-08-22 2016-11-09 Theracos Sub Llc Processos para a preparação de inibidores de sglt2
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
ES2746480T3 (es) * 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
CA2800176C (en) 2010-05-24 2018-08-28 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
AU2012253834B2 (en) * 2011-05-06 2016-06-16 Glaxosmithkline Consumer Healthcare (Uk) Ip Limited Sustained release paracetamol formulations
PH12013502325A1 (en) 2011-05-13 2014-02-10 Eb Ip Hybritabs B V Drug delivery system
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR102035877B1 (ko) 2011-11-14 2019-10-23 알파시그마 에스.피.에이. 우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
SMT202400056T1 (it) * 2018-07-30 2024-03-13 Biothea Pharma Inc Sale cristallino di malonato di epinefrina
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
CN1406126A (zh) 1998-10-01 2003-03-26 诺瓦提斯公司 新型缓释口服制剂
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
AU6332199A (en) 2000-04-26
SK4392001A3 (en) 2002-07-02
AU764866B2 (en) 2003-09-04
KR20010073168A (ko) 2001-07-31
US20030039692A1 (en) 2003-02-27
EP1121104A2 (en) 2001-08-08
EP1121104B1 (en) 2005-01-12
WO2000019985A3 (en) 2000-07-20
HUP0103883A2 (hu) 2002-05-29
TR200100931T2 (tr) 2001-10-22
WO2000019985A2 (en) 2000-04-13
HK1052473A1 (zh) 2003-09-19
JP2002526402A (ja) 2002-08-20
US20070053982A1 (en) 2007-03-08
ID27504A (id) 2001-04-12
US20010033866A1 (en) 2001-10-25
NO20011471L (no) 2001-03-22
NZ510683A (en) 2003-09-26
US20030203025A1 (en) 2003-10-30
ES2237163T3 (es) 2005-07-16
CN1406126A (zh) 2003-03-26
CA2342340A1 (en) 2000-04-13
NO20011471D0 (no) 2001-03-22
SK285250B6 (sk) 2006-09-07
HUP0103883A3 (en) 2002-11-28
DE69923200T2 (de) 2005-12-22
ATE286725T1 (de) 2005-01-15
IL141762A (en) 2010-06-30
US20050175706A1 (en) 2005-08-11
IL141762A0 (en) 2002-03-10
NO331689B1 (no) 2012-02-27
CZ20011155A3 (cs) 2001-08-15
US6565883B2 (en) 2003-05-20
PT1121104E (pt) 2005-05-31
PL196945B1 (pl) 2008-02-29
KR100603900B1 (ko) 2006-07-25
CA2342340C (en) 2006-08-29
DE69923200D1 (de) 2005-02-17
JP4012689B2 (ja) 2007-11-21
CZ302888B6 (cs) 2012-01-11
PL348734A1 (en) 2002-06-03

Similar Documents

Publication Publication Date Title
PL348734A1 (en) New sustained release oral formulations
BR0005938A (pt) Composição de dosagem oral com libaraçãoprolongada
AP1954A (en) Controlled release compositions comprising nimesulide.
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
BR9810495A (pt) Composição farmacêutica
FI973518A7 (fi) Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa
BR9806212A (pt) Composições farmacêuticas sólidas compreendendo uma ciclosporina e um surfactante aniÈnico.
GEP20053473B (en) High Potency Dihydroergotamine Compositions
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
IL150895A0 (en) Oral, nasal and pulmonary formulations of copolymer-1
DK1073467T3 (da) Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
BR0014440A (pt) Formulações de liberação controlada oral
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
PL348202A1 (en) Pharmaceutically active composition and dispensing device
BR9812385A (pt) Formulações parasiticidas
GEP20043377B (en) Pharmaceutical Complex
FR2759587B1 (fr) Composition pharmaceutique pour l&#39;administration buccale de thiocolchicoside
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
BR9809286A (pt) Processos para redução de fibrinogênio
DE50311479D1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
BR9805026A (pt) Compostos contdndo tetrahidrolipstatina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ARTS. 8O E 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]